U.S. FDA approves Krystal Biotech's skin disorder gene therapy

Krystal Biotech

19/05/2023 18:55

May 19 (Reuters) - The U.S. Food and Drug Administration
approved Krystal Biotech Inc's  KRYS.O  topical gene therapy for
patients with a genetic skin disorder, making it the first of
its kind to receive the health regulator's approval. 

 (Reporting by Pratik Jain in Bengaluru; Editing by Shailesh
Kuber)
 ((Pratik.Jain@thomsonreuters.com;))